Gastric Dysplasia Clinical Trial
Official title:
Ablation of Gastric Dysplastic Mucosa by a Novel Endoscopic Radiofrequency Device.
The finding of gastric dysplasia not associated with macroscopic lesions (DNAML) or the follow-up of dysplasia after endoscopic resection (DAER) is a challenging dilemma. In the last few years, radiofrequency ablation (RFA) has become a recognized tool in the treatment of dysplastic Barrett's esophagus, but its use in gastric dysplasia has not yet been studied. The investigators aim to study the efficacy, safety and tolerability of RFA in the treatment of dysplastic gastric mucosa.
Gastric cancer is the fourth most common cancer and the second leading cause of cancer
related death worldwide. The 10-year survival of patients with this malignancy is 20% due to
advanced disease at the time of diagnosis. Screening programs in countries with a high
incidence of gastric neoplasia aim to detect early stage cancer, suitable for curative
treatment. Well-differentiated dysplastic gastric lesions limited to the mucosa (when
non-ulcerated or ulcerated and less than 3 cm) or limited to the superficial submucosa (when
less than 3 cm and with no lymphatic or vascular invasion) have a negligible risk of lymph
node metastasis and are suitable for endoscopic curative treatment.
Endoscopic mucosal resection (EMR) and endoscopic submucosal dissection (ESD) have been
increasingly used in this setting with promising results. However, even with these advanced
techniques, en bloc and R0 resection is not possible in up to 13-15% and 16-26% of the
cases, respectively. The presence of dysplasia after endoscopic resection (DAER) in the
post-resection scar presents a challenging dilemma due to the technical difficulty, and
associated complications, of performing subsequent EMR/ESD in fibrotic tissue. Another issue
of concern is the presence of gastric dysplasia not associated with macroscopic lesions
(DNAML). In such cases, a targeted endoscopic treatment is difficult and clinical management
is not standardized.
Radiofrequency ablation (RFA) has been increasingly advocated for the treatment of
dysplastic Barrett's esophagus (BE) and early esophageal squamous cell carcinoma (ESCC), but
its use in gastric dysplasia has not yet been tested. The investigators aim to study the
role of gastric RFA in the treatment of DNAML and DAER.
;
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00339989 -
Cervical Cancer Early Endpoints and Determinants
|
||
Completed |
NCT01954836 -
Short-Term Fasting During Chemotherapy in Patients With Gynecological Cancer- a Randomized Controlled Cross-over Trial
|
N/A | |
Not yet recruiting |
NCT03979014 -
Nonavalent Prophylactic HPV Vaccine (GARDASIL9) After Local Conservative The NOVEL Trial
|
Phase 3 | |
Completed |
NCT02065297 -
Quantitative and Functional Study of TH17 Lymphocytes in Horton's Disease (HD)
|
||
Recruiting |
NCT02049658 -
The Sensitivity and Specificity of Sniff Dog as a Tool in Diagnosing the Suspected Tumor Patients
|
||
Recruiting |
NCT02049645 -
The Suitability of Sniff Dog as a Tool in Screening Tumors
|
||
Completed |
NCT03415126 -
A Study of ASN007 in Patients With Advanced Solid Tumors
|
Phase 1 | |
Enrolling by invitation |
NCT00792649 -
Comparison Between HD+ Endoscopy and Standard Videoendoscopy in Screening Colonoscopy
|
N/A | |
Recruiting |
NCT05158712 -
Genetic Factors and Pheochromocytomas in Neoplasia Type 2
|
||
Completed |
NCT01962103 -
Study to Find a Safe Dose and Show Early Clinical Activity of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent/ Refractory Solid Tumors
|
Phase 1/Phase 2 | |
Terminated |
NCT01456143 -
Optical Imaging of Head and Neck Cancer
|
N/A | |
Recruiting |
NCT04341181 -
ProTarget - A Danish Nationwide Clinical Trial on Targeted Cancer Treatment Based on Genomic Profiling
|
Phase 2 | |
Recruiting |
NCT02925234 -
The Drug Rediscovery Protocol (DRUP Trial)
|
Phase 2 |